RU2014143242A - Производные фенилмочевины и фенилкарбаматов в качестве ингибиторов агрегации белка - Google Patents
Производные фенилмочевины и фенилкарбаматов в качестве ингибиторов агрегации белка Download PDFInfo
- Publication number
- RU2014143242A RU2014143242A RU2014143242A RU2014143242A RU2014143242A RU 2014143242 A RU2014143242 A RU 2014143242A RU 2014143242 A RU2014143242 A RU 2014143242A RU 2014143242 A RU2014143242 A RU 2014143242A RU 2014143242 A RU2014143242 A RU 2014143242A
- Authority
- RU
- Russia
- Prior art keywords
- ethyl
- indol
- urea
- methylpiperazin
- methyl
- Prior art date
Links
- 230000004845 protein aggregation Effects 0.000 title claims 2
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical class OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 12
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 11
- 229910052736 halogen Inorganic materials 0.000 claims abstract 11
- 150000002367 halogens Chemical group 0.000 claims abstract 11
- 125000001424 substituent group Chemical group 0.000 claims abstract 9
- 125000003277 amino group Chemical group 0.000 claims abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract 5
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 3
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 2
- -1 1H-benzimidazolyl Chemical group 0.000 claims 12
- 125000004429 atom Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- RBYNETHHEMQMNK-UHFFFAOYSA-N 1-(2-aminoethyl)-3-[3-ethyl-4-(1h-indol-3-ylmethyl)phenyl]urea Chemical compound CCC1=CC(NC(=O)NCCN)=CC=C1CC1=CNC2=CC=CC=C12 RBYNETHHEMQMNK-UHFFFAOYSA-N 0.000 claims 1
- GJXOQMNHEKHGFM-UHFFFAOYSA-N 1-[3-(1h-indol-2-ylmethoxy)-5-propoxyphenyl]-3-(2-piperazin-1-ylethyl)urea Chemical compound C=1C(OCC=2NC3=CC=CC=C3C=2)=CC(OCCC)=CC=1NC(=O)NCCN1CCNCC1 GJXOQMNHEKHGFM-UHFFFAOYSA-N 0.000 claims 1
- KPKZFNMOWJGMGI-UHFFFAOYSA-N 1-[3-(1h-indol-2-ylmethoxy)-5-propoxyphenyl]-3-(2-piperidin-4-ylethyl)urea Chemical compound C=1C(OCC=2NC3=CC=CC=C3C=2)=CC(OCCC)=CC=1NC(=O)NCCC1CCNCC1 KPKZFNMOWJGMGI-UHFFFAOYSA-N 0.000 claims 1
- YKQHEDNVQMHJLH-UHFFFAOYSA-N 1-[3-(1h-indol-2-ylmethoxy)-5-propoxyphenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]thiourea Chemical compound C=1C(OCC=2NC3=CC=CC=C3C=2)=CC(OCCC)=CC=1NC(=S)NCCN1CCN(C)CC1 YKQHEDNVQMHJLH-UHFFFAOYSA-N 0.000 claims 1
- QYOKBBSVTMCTLM-UHFFFAOYSA-N 1-[3-(1h-indol-2-ylmethoxy)-5-propoxyphenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(OCC=2NC3=CC=CC=C3C=2)=CC(OCCC)=CC=1NC(=O)NCCN1CCN(C)CC1 QYOKBBSVTMCTLM-UHFFFAOYSA-N 0.000 claims 1
- CVGWWSWCDADCHQ-UHFFFAOYSA-N 1-[3-(1h-indol-3-ylmethyl)-5-methoxyphenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(OC)=CC(CC=2C3=CC=CC=C3NC=2)=CC=1NC(=O)NCCN1CCN(C)CC1 CVGWWSWCDADCHQ-UHFFFAOYSA-N 0.000 claims 1
- NXJSXLOWXWJKAV-UHFFFAOYSA-N 1-[3-(1h-indol-3-ylmethyl)-5-propan-2-yloxyphenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(OC(C)C)=CC(CC=2C3=CC=CC=C3NC=2)=CC=1NC(=O)NCCN1CCN(C)CC1 NXJSXLOWXWJKAV-UHFFFAOYSA-N 0.000 claims 1
- OEWMTCRSEPVHFY-UHFFFAOYSA-N 1-[3-[2-(1h-indol-3-yl)ethyl]-5-propan-2-ylphenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]thiourea Chemical compound C=1C(C(C)C)=CC(CCC=2C3=CC=CC=C3NC=2)=CC=1NC(=S)NCCN1CCN(C)CC1 OEWMTCRSEPVHFY-UHFFFAOYSA-N 0.000 claims 1
- QVPSBZWFQYGAKC-UHFFFAOYSA-N 1-[3-butyl-4-(1h-indol-3-ylmethyl)-5-(trifluoromethoxy)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(OC(F)(F)F)=C(CC=2C3=CC=CC=C3NC=2)C(CCCC)=CC=1NC(=O)NCCN1CCN(C)CC1 QVPSBZWFQYGAKC-UHFFFAOYSA-N 0.000 claims 1
- GGBQZKQFGCFYRL-UHFFFAOYSA-N 1-[3-butyl-4-(1h-indol-3-ylmethyl)-5-methoxyphenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(OC)=C(CC=2C3=CC=CC=C3NC=2)C(CCCC)=CC=1NC(=O)NCCN1CCN(C)CC1 GGBQZKQFGCFYRL-UHFFFAOYSA-N 0.000 claims 1
- VAGAPCWJTBONAS-UHFFFAOYSA-N 1-[3-butyl-5-(1h-imidazo[4,5-b]pyrazin-2-ylmethyl)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(CCCC)=CC(CC=2NC3=NC=CN=C3N=2)=CC=1NC(=O)NCCN1CCN(C)CC1 VAGAPCWJTBONAS-UHFFFAOYSA-N 0.000 claims 1
- DRKVIPKWAHSPMY-UHFFFAOYSA-N 1-[3-butyl-5-(1h-indol-3-ylmethoxy)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(OCC=2C3=CC=CC=C3NC=2)=CC(CCCC)=CC=1NC(=O)NCCN1CCN(C)CC1 DRKVIPKWAHSPMY-UHFFFAOYSA-N 0.000 claims 1
- QAKMKLOSXMOKPU-UHFFFAOYSA-N 1-[3-butyl-5-(1h-indol-3-ylmethyl)phenyl]-3-(2-piperidin-4-ylethyl)urea Chemical compound C=1C(CCCC)=CC(CC=2C3=CC=CC=C3NC=2)=CC=1NC(=O)NCCC1CCNCC1 QAKMKLOSXMOKPU-UHFFFAOYSA-N 0.000 claims 1
- DSDXCHSRGHORBB-UHFFFAOYSA-N 1-[3-butyl-5-(2,3-dihydro-1h-benzimidazol-2-ylmethyl)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(CCCC)=CC(CC2NC3=CC=CC=C3N2)=CC=1NC(=O)NCCN1CCN(C)CC1 DSDXCHSRGHORBB-UHFFFAOYSA-N 0.000 claims 1
- BUMROPPMYBHLLF-UHFFFAOYSA-N 1-[3-butyl-5-hydroxy-4-(1h-indol-3-ylmethyl)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C(O)=C(CC=2C3=CC=CC=C3NC=2)C(CCCC)=CC=1NC(=O)NCCN1CCN(C)CC1 BUMROPPMYBHLLF-UHFFFAOYSA-N 0.000 claims 1
- ZHPUPZFRXZBEKU-UHFFFAOYSA-N 1-[3-cyclohexyloxy-5-(1h-indol-3-ylmethyl)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C1CN(C)CCN1CCNC(=O)NC1=CC(CC=2C3=CC=CC=C3NC=2)=CC(OC2CCCCC2)=C1 ZHPUPZFRXZBEKU-UHFFFAOYSA-N 0.000 claims 1
- RDXTURUZNDFRCO-UHFFFAOYSA-N 1-[3-cyclopentyloxy-5-(1h-indol-3-ylmethyl)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C1CN(C)CCN1CCNC(=O)NC1=CC(CC=2C3=CC=CC=C3NC=2)=CC(OC2CCCC2)=C1 RDXTURUZNDFRCO-UHFFFAOYSA-N 0.000 claims 1
- LWYSHXBDBGXEDU-UHFFFAOYSA-N 1-[3-cyclopropyloxy-5-(1h-indol-3-ylmethyl)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C1CN(C)CCN1CCNC(=O)NC1=CC(CC=2C3=CC=CC=C3NC=2)=CC(OC2CC2)=C1 LWYSHXBDBGXEDU-UHFFFAOYSA-N 0.000 claims 1
- SRSIGTFBRAKBIH-UHFFFAOYSA-N 1-[3-ethyl-4-(1h-indol-3-ylmethyl)phenyl]-3-(2-piperazin-1-ylethyl)urea Chemical compound C=1C=C(CC=2C3=CC=CC=C3NC=2)C(CC)=CC=1NC(=O)NCCN1CCNCC1 SRSIGTFBRAKBIH-UHFFFAOYSA-N 0.000 claims 1
- DLRKIDHQJPSZET-UHFFFAOYSA-N 1-[3-ethyl-4-(1h-indol-3-ylmethyl)phenyl]-3-[2-(1h-imidazol-5-yl)ethyl]urea Chemical compound C=1C=C(CC=2C3=CC=CC=C3NC=2)C(CC)=CC=1NC(=O)NCCC1=CN=CN1 DLRKIDHQJPSZET-UHFFFAOYSA-N 0.000 claims 1
- FKFSPCZNABVGFH-UHFFFAOYSA-N 1-[3-ethyl-4-(1h-indol-3-ylmethyl)phenyl]-3-[2-(4-methylpiperazin-1-yl)ethyl]urea Chemical compound C=1C=C(CC=2C3=CC=CC=C3NC=2)C(CC)=CC=1NC(=O)NCCN1CCN(C)CC1 FKFSPCZNABVGFH-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616771P | 2012-03-28 | 2012-03-28 | |
| US61/616,771 | 2012-03-28 | ||
| PCT/US2013/032552 WO2013148365A1 (en) | 2012-03-28 | 2013-03-15 | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014143242A true RU2014143242A (ru) | 2016-05-20 |
Family
ID=49261100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014143242A RU2014143242A (ru) | 2012-03-28 | 2013-03-15 | Производные фенилмочевины и фенилкарбаматов в качестве ингибиторов агрегации белка |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9527852B2 (enExample) |
| EP (1) | EP2830608B8 (enExample) |
| JP (1) | JP6159388B2 (enExample) |
| KR (1) | KR20150002713A (enExample) |
| CN (1) | CN104363903A (enExample) |
| AU (1) | AU2013240219A1 (enExample) |
| CA (1) | CA2867175A1 (enExample) |
| ES (1) | ES2768602T3 (enExample) |
| HK (1) | HK1202452A1 (enExample) |
| IL (1) | IL234825A0 (enExample) |
| IN (1) | IN2014DN08633A (enExample) |
| MX (1) | MX2014011615A (enExample) |
| NZ (1) | NZ631388A (enExample) |
| RU (1) | RU2014143242A (enExample) |
| WO (1) | WO2013148365A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57533B1 (sr) | 2014-01-29 | 2018-10-31 | Ucb Biopharma Sprl | Heteroaril amidi kao inhibitori proteinske agregacije |
| WO2016040780A1 (en) * | 2014-09-11 | 2016-03-17 | Neuropore Therapies, Inc. | Aminomethyl- and methyloxy-linked tricyclic compounds as inhibitors of protein aggregation |
| WO2017020010A1 (en) | 2015-07-29 | 2017-02-02 | Neuropore Therapies, Inc. | Bis-heteroaryl derivatives as modulators of protein aggregation |
| BR112019011932A2 (pt) | 2017-01-26 | 2019-10-29 | Ucb Biopharma Sprl | derivados de bis-heteroarila como moduladores da agregação de proteína |
| ES2884145T3 (es) | 2017-01-26 | 2021-12-10 | UCB Biopharma SRL | Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas |
| JP7100042B2 (ja) | 2017-01-26 | 2022-07-12 | ユーシービー バイオファルマ エスアールエル | タンパク質凝集のモジュレーターとしてのアルコキシビス－ヘテロアリール誘導体 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59712297D1 (de) * | 1996-01-26 | 2005-06-09 | Altana Pharma Ag | 3-alkylimidazopyridine |
| US6617351B1 (en) * | 1998-07-31 | 2003-09-09 | Eli Lilly And Company | Amide, carbamate, and urea derivatives |
| CA2389360C (en) | 1999-11-16 | 2008-06-03 | Steffen Breitfelder | Urea derivatives as anti-inflammatory agents |
| GB2384776C (en) * | 2000-10-30 | 2006-02-03 | Kudos Pharm Ltd | Phthalazinone derivatives |
| EP1402888A1 (en) * | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
| JP2006520333A (ja) * | 2003-03-14 | 2006-09-07 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたアニリン誘導体 |
| MXPA05010000A (es) * | 2003-03-21 | 2005-11-17 | Lundbeck & Co As H | Derivados de p-diaminobenceno substituidos. |
| EP1684762A4 (en) * | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| PL1893612T3 (pl) | 2005-06-22 | 2012-01-31 | Plexxikon Inc | Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| WO2007124423A2 (en) | 2006-04-21 | 2007-11-01 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| EP2513090A1 (en) * | 2009-12-16 | 2012-10-24 | Neuropore Therapies, Inc. | Compound suitable for the treatment of synucleopathies |
-
2013
- 2013-03-15 NZ NZ631388A patent/NZ631388A/en not_active IP Right Cessation
- 2013-03-15 ES ES13768915T patent/ES2768602T3/es active Active
- 2013-03-15 RU RU2014143242A patent/RU2014143242A/ru not_active Application Discontinuation
- 2013-03-15 CN CN201380017441.6A patent/CN104363903A/zh active Pending
- 2013-03-15 EP EP13768915.4A patent/EP2830608B8/en active Active
- 2013-03-15 KR KR1020147030291A patent/KR20150002713A/ko not_active Withdrawn
- 2013-03-15 WO PCT/US2013/032552 patent/WO2013148365A1/en not_active Ceased
- 2013-03-15 HK HK15103189.8A patent/HK1202452A1/xx unknown
- 2013-03-15 CA CA2867175A patent/CA2867175A1/en not_active Abandoned
- 2013-03-15 US US14/388,783 patent/US9527852B2/en active Active
- 2013-03-15 AU AU2013240219A patent/AU2013240219A1/en not_active Abandoned
- 2013-03-15 JP JP2015503346A patent/JP6159388B2/ja active Active
- 2013-03-15 MX MX2014011615A patent/MX2014011615A/es unknown
-
2014
- 2014-09-23 IL IL234825A patent/IL234825A0/en unknown
- 2014-10-15 IN IN8633DEN2014 patent/IN2014DN08633A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150166543A1 (en) | 2015-06-18 |
| KR20150002713A (ko) | 2015-01-07 |
| JP6159388B2 (ja) | 2017-07-05 |
| EP2830608B1 (en) | 2019-12-11 |
| ES2768602T3 (es) | 2020-06-23 |
| US9527852B2 (en) | 2016-12-27 |
| HK1202452A1 (en) | 2015-10-02 |
| IL234825A0 (en) | 2014-12-31 |
| IN2014DN08633A (enExample) | 2015-05-22 |
| NZ631388A (en) | 2016-01-29 |
| CN104363903A (zh) | 2015-02-18 |
| JP2015515465A (ja) | 2015-05-28 |
| EP2830608B8 (en) | 2020-01-15 |
| CA2867175A1 (en) | 2013-10-03 |
| EP2830608A1 (en) | 2015-02-04 |
| AU2013240219A1 (en) | 2014-10-09 |
| WO2013148365A1 (en) | 2013-10-03 |
| MX2014011615A (es) | 2015-01-19 |
| EP2830608A4 (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507122A5 (enExample) | ||
| RU2014143242A (ru) | Производные фенилмочевины и фенилкарбаматов в качестве ингибиторов агрегации белка | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| ZA202007154B (en) | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases | |
| HRP20180916T1 (hr) | Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba | |
| EA200970598A1 (ru) | Замещенные производные гетероарилпиридопиримидона | |
| HRP20100677T1 (hr) | IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 | |
| JP2011513305A5 (enExample) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| MX348548B (es) | Derivado heterociclico y farmaceutico. | |
| HRP20140884T1 (hr) | Derivati fenoksipiridinilamida i njihova primjena u lijeäśenju bolesnih stanja posredovanih inhibitorima pde4 | |
| RU2012116584A (ru) | Лизинспецифические ингибиторы деметилазы-1 и их применение | |
| CA2683696A1 (en) | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity | |
| NZ600416A (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| JP2019505541A5 (enExample) | ||
| NZ703941A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| JP2014516360A5 (enExample) | ||
| CA2451980A1 (en) | 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune disorders | |
| JP2011219498A5 (enExample) | ||
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| JP2006511446A5 (enExample) | ||
| JP2012505234A5 (enExample) | ||
| RU2012125971A (ru) | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных | |
| NZ600365A (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170713 |